PFM Health Sciences
VC Fund
San Francisco, United States
PFM Health Sciences is an investment management firm specializing in global healthcare strategies. The firm was founded in 2004 and is headquartered in San Francisco, California, United States.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries PFM Health Sciences invests in
Stages PFM Health Sciences invests in
Countries PFM Health Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anant Ahuja
|
|||
|
Brian Grossman
|
|||
Investment Focus
Industry
- Health Care 14 (58%)
- Biotechnology 12 (50%)
- Medical 8 (33%)
- Therapeutics 6 (25%)
- Artificial Intelligence 5 (21%)
Stage
- Series C 7 (29%)
- Series B 5 (21%)
- Series D 4 (17%)
- Post-IPO Equity 3 (13%)
- Series A 1 (4%)
Country
- United States 17 (71%)
- United Kingdom 2 (8%)
- Denmark 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anant Ahuja
Partner
|
Partner | Total investments: 1 | Find email | |
|
Brian Grossman
Founder, Managing Partner, CIO, Fund Manager & Portfolio Manager
|
Founder, Managing Partner, CIO, Fund Manager & Portfolio Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Apella Technology
|
Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $80M / Series B / Jan 07, 2026 | |
Outset Medical
|
Outset Medical is a pioneering medical technology company that manufactures medical equipment. The company reimagining dialysis for patients and health care providers. The innovative, compact, user-friendly Tablo Hemodialysis System can deliver both acute and chronic dialysis, wherever you need it.Through the versatile, all-in-one TabloHemodialysis System, they are using innovative technology to drive service model innovation, aimed at reducing cost and transforming the patient care experience. The system comes equipped with wireless data, sensor-based automation, and an animated touchscreen to make the system as easy to use as possible. | $168.8M / Post-IPO Equity / Jan 06, 2025 | |
Mendaera
|
Mendaera is a medtech startup that focuses on developing advanced healthcare technologies, particularly in robotics and diagnostic tools. Mendaera envisions digitizing clinical judgment and technical expertise to ensure that high-quality care is accessible to every patient, in every care facility. Their platform, currently in development,integrates robotics, AI, real-time imaging, and connectivity to enable medical interventions at scale. | $73M / Series B / Sep 26, 2024 | |
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $80M / Series C / Aug 15, 2024 | |
Tenaya Therapeutics
|
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration,enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies. | $50M / Post-IPO Equity / Feb 08, 2024 | |
COMPASS Pathways
|
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression.Compass Pathways conducts clinical trials and research toassess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression. | $125M / Post-IPO Equity / Aug 16, 2023 | |
Boundless Bio
|
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $100M / Series C / May 16, 2023 | |
Metagenomi
|
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $100M / Series B / Jan 05, 2023 | |
Escient Pharmaceuticals
|
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M / Series C / Nov 28, 2022 | |
|
Metagenomi
|
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M / Series B / Jan 25, 2022 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does PFM Health Sciences invest in?
PFM Health Sciences invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact PFM Health Sciences?
Public channels for PFM Health Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PFM Health Sciences?
The team at PFM Health Sciences includes Anant Ahuja (Partner) and Brian Grossman (Founder, Managing Partner, CIO, Fund Manager & Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
